{"id": "train_5_261", "text": "In @DISEASE$ patients, @GENE$-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.", "text_with_entity_marker": "In [E1]@DISEASE$[/E1] patients, [E2]@GENE$[/E2]-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.", "text_with_typed_entity_marker": "In [DISEASE]@DISEASE$[/DISEASE] patients, [GENE]@GENE$[/GENE]-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@DISEASE$", "entity_1_idx": [3, 12], "entity_1_idx_in_text_with_entity_marker": [7, 16], "entity_1_idx_in_text_with_typed_entity_marker": [12, 21], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [23, 29], "entity_2_idx_in_text_with_entity_marker": [36, 42], "entity_2_idx_in_text_with_typed_entity_marker": [48, 54], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_67", "text": "However, the contribution of common genetic variants in @GENE$ to the @DISEASE$ risk in Chinese populations has not been thoroughly investigated.", "text_with_entity_marker": "However, the contribution of common genetic variants in [E1]@GENE$[/E1] to the [E2]@DISEASE$[/E2] risk in Chinese populations has not been thoroughly investigated.", "text_with_typed_entity_marker": "However, the contribution of common genetic variants in [GENE]@GENE$[/GENE] to the [DISEASE]@DISEASE$[/DISEASE] risk in Chinese populations has not been thoroughly investigated.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [56, 62], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_idx_in_text_with_typed_entity_marker": [62, 68], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [70, 79], "entity_2_idx_in_text_with_entity_marker": [83, 92], "entity_2_idx_in_text_with_typed_entity_marker": [92, 101], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_62", "text": "In contrast, the @GENE$ genotype was not associated with @DISEASE$ viremia or with the HCV core antigen level.", "text_with_entity_marker": "In contrast, the [E1]@GENE$[/E1] genotype was not associated with [E2]@DISEASE$[/E2] viremia or with the HCV core antigen level.", "text_with_typed_entity_marker": "In contrast, the [GENE]@GENE$[/GENE] genotype was not associated with [DISEASE]@DISEASE$[/DISEASE] viremia or with the HCV core antigen level.", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@GENE$", "entity_1_idx": [17, 23], "entity_1_idx_in_text_with_entity_marker": [21, 27], "entity_1_idx_in_text_with_typed_entity_marker": [23, 29], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [57, 66], "entity_2_idx_in_text_with_entity_marker": [70, 79], "entity_2_idx_in_text_with_typed_entity_marker": [79, 88], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_118", "text": "Functional studies to unravel the biological significance of this region in regulating @GENE$ production is clearly indicated, which may lead to new strategies to modify the disease course of severe @DISEASE$.", "text_with_entity_marker": "Functional studies to unravel the biological significance of this region in regulating [E1]@GENE$[/E1] production is clearly indicated, which may lead to new strategies to modify the disease course of severe [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "Functional studies to unravel the biological significance of this region in regulating [GENE]@GENE$[/GENE] production is clearly indicated, which may lead to new strategies to modify the disease course of severe [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@GENE$", "entity_1_idx": [87, 93], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_idx_in_text_with_typed_entity_marker": [93, 99], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [199, 208], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_idx_in_text_with_typed_entity_marker": [221, 230], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_43", "text": "The low frequencies of the at-risk alleles at rs1048661 and @GENE$ may be one of the factors that led to the low prevalence of @DISEASE$ in the general populations of the Chinese.", "text_with_entity_marker": "The low frequencies of the at-risk alleles at rs1048661 and [E1]@GENE$[/E1] may be one of the factors that led to the low prevalence of [E2]@DISEASE$[/E2] in the general populations of the Chinese.", "text_with_typed_entity_marker": "The low frequencies of the at-risk alleles at rs1048661 and [GENE]@GENE$[/GENE] may be one of the factors that led to the low prevalence of [DISEASE]@DISEASE$[/DISEASE] in the general populations of the Chinese.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [60, 66], "entity_1_idx_in_text_with_entity_marker": [64, 70], "entity_1_idx_in_text_with_typed_entity_marker": [66, 72], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [127, 136], "entity_2_idx_in_text_with_entity_marker": [140, 149], "entity_2_idx_in_text_with_typed_entity_marker": [149, 158], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_84", "text": "The @GENE$ polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and @DISEASE$.", "text_with_entity_marker": "The [E1]@GENE$[/E1] polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "The [GENE]@GENE$[/GENE] polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [4, 10], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_idx_in_text_with_typed_entity_marker": [10, 16], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [218, 227], "entity_2_idx_in_text_with_entity_marker": [231, 240], "entity_2_idx_in_text_with_typed_entity_marker": [240, 249], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_100", "text": "Genetic variations in @GENE$ were identified and genotyped in 295 unrelated patients with @DISEASE$ and 180 control subjects.", "text_with_entity_marker": "Genetic variations in [E1]@GENE$[/E1] were identified and genotyped in 295 unrelated patients with [E2]@DISEASE$[/E2] and 180 control subjects.", "text_with_typed_entity_marker": "Genetic variations in [GENE]@GENE$[/GENE] were identified and genotyped in 295 unrelated patients with [DISEASE]@DISEASE$[/DISEASE] and 180 control subjects.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [22, 28], "entity_1_idx_in_text_with_entity_marker": [26, 32], "entity_1_idx_in_text_with_typed_entity_marker": [28, 34], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [90, 99], "entity_2_idx_in_text_with_entity_marker": [103, 112], "entity_2_idx_in_text_with_typed_entity_marker": [112, 121], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_226", "text": "Two hundred and twenty-three incident @DISEASE$ cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, @GENE$, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "text_with_entity_marker": "Two hundred and twenty-three incident [E1]@DISEASE$[/E1] cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, [E2]@GENE$[/E2], TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "text_with_typed_entity_marker": "Two hundred and twenty-three incident [DISEASE]@DISEASE$[/DISEASE] cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, [GENE]@GENE$[/GENE], TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@DISEASE$", "entity_1_idx": [38, 47], "entity_1_idx_in_text_with_entity_marker": [42, 51], "entity_1_idx_in_text_with_typed_entity_marker": [47, 56], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [290, 296], "entity_2_idx_in_text_with_entity_marker": [303, 309], "entity_2_idx_in_text_with_typed_entity_marker": [315, 321], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_294", "text": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with @DISEASE$ to the same extent as FcGIIIA G559T and @GENE$.", "text_with_entity_marker": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with [E1]@DISEASE$[/E1] to the same extent as FcGIIIA G559T and [E2]@GENE$[/E2].", "text_with_typed_entity_marker": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with [DISEASE]@DISEASE$[/DISEASE] to the same extent as FcGIIIA G559T and [GENE]@GENE$[/GENE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@DISEASE$", "entity_1_idx": [164, 173], "entity_1_idx_in_text_with_entity_marker": [168, 177], "entity_1_idx_in_text_with_typed_entity_marker": [173, 182], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [214, 220], "entity_2_idx_in_text_with_entity_marker": [227, 233], "entity_2_idx_in_text_with_typed_entity_marker": [239, 245], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_164", "text": "Vascular endothelial growth factor (VEGF) promotes @DISEASE$ progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (@GENE$) expressed on tumour cells.", "text_with_entity_marker": "Vascular endothelial growth factor (VEGF) promotes [E1]@DISEASE$[/E1] progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 ([E2]@GENE$[/E2]) expressed on tumour cells.", "text_with_typed_entity_marker": "Vascular endothelial growth factor (VEGF) promotes [DISEASE]@DISEASE$[/DISEASE] progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 ([GENE]@GENE$[/GENE]) expressed on tumour cells.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@DISEASE$", "entity_1_idx": [51, 60], "entity_1_idx_in_text_with_entity_marker": [55, 64], "entity_1_idx_in_text_with_typed_entity_marker": [60, 69], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [199, 205], "entity_2_idx_in_text_with_entity_marker": [212, 218], "entity_2_idx_in_text_with_typed_entity_marker": [224, 230], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_207", "text": "Toll-like receptor-induced @GENE$ secretion is impaired in @DISEASE$ by nucleotide oligomerization domain 2-dependent and -independent pathways.", "text_with_entity_marker": "Toll-like receptor-induced [E1]@GENE$[/E1] secretion is impaired in [E2]@DISEASE$[/E2] by nucleotide oligomerization domain 2-dependent and -independent pathways.", "text_with_typed_entity_marker": "Toll-like receptor-induced [GENE]@GENE$[/GENE] secretion is impaired in [DISEASE]@DISEASE$[/DISEASE] by nucleotide oligomerization domain 2-dependent and -independent pathways.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [27, 33], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_idx_in_text_with_typed_entity_marker": [33, 39], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [59, 68], "entity_2_idx_in_text_with_entity_marker": [72, 81], "entity_2_idx_in_text_with_typed_entity_marker": [81, 90], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_200", "text": "@GENE$ is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (@DISEASE$).", "text_with_entity_marker": "[E1]@GENE$[/E1] is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma ([E2]@DISEASE$[/E2]).", "text_with_typed_entity_marker": "[GENE]@GENE$[/GENE] is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma ([DISEASE]@DISEASE$[/DISEASE]).", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [0, 6], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_idx_in_text_with_typed_entity_marker": [6, 12], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [103, 112], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_idx_in_text_with_typed_entity_marker": [125, 134], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_311", "text": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of @DISEASE$ and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a @GENE$-dependent disease risk factor.", "text_with_entity_marker": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of [E1]@DISEASE$[/E1] and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a [E2]@GENE$[/E2]-dependent disease risk factor.", "text_with_typed_entity_marker": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of [DISEASE]@DISEASE$[/DISEASE] and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a [GENE]@GENE$[/GENE]-dependent disease risk factor.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@DISEASE$", "entity_1_idx": [95, 104], "entity_1_idx_in_text_with_entity_marker": [99, 108], "entity_1_idx_in_text_with_typed_entity_marker": [104, 113], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [196, 202], "entity_2_idx_in_text_with_entity_marker": [209, 215], "entity_2_idx_in_text_with_typed_entity_marker": [221, 227], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_128", "text": "IL-1, IL-1R and @GENE$ in Iranian patients with @DISEASE$.", "text_with_entity_marker": "IL-1, IL-1R and [E1]@GENE$[/E1] in Iranian patients with [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "IL-1, IL-1R and [GENE]@GENE$[/GENE] in Iranian patients with [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [16, 22], "entity_1_idx_in_text_with_entity_marker": [20, 26], "entity_1_idx_in_text_with_typed_entity_marker": [22, 28], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [48, 57], "entity_2_idx_in_text_with_entity_marker": [61, 70], "entity_2_idx_in_text_with_typed_entity_marker": [70, 79], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_256", "text": "@GENE$ genetic variations and susceptibility to @DISEASE$ in a Chinese population.", "text_with_entity_marker": "[E1]@GENE$[/E1] genetic variations and susceptibility to [E2]@DISEASE$[/E2] in a Chinese population.", "text_with_typed_entity_marker": "[GENE]@GENE$[/GENE] genetic variations and susceptibility to [DISEASE]@DISEASE$[/DISEASE] in a Chinese population.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [0, 6], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_idx_in_text_with_typed_entity_marker": [6, 12], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [48, 57], "entity_2_idx_in_text_with_entity_marker": [61, 70], "entity_2_idx_in_text_with_typed_entity_marker": [70, 79], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_151", "text": "Two hundred and twenty-three incident @DISEASE$ cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes @GENE$ (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "text_with_entity_marker": "Two hundred and twenty-three incident [E1]@DISEASE$[/E1] cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes [E2]@GENE$[/E2] (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "text_with_typed_entity_marker": "Two hundred and twenty-three incident [DISEASE]@DISEASE$[/DISEASE] cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes [GENE]@GENE$[/GENE] (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@DISEASE$", "entity_1_idx": [38, 47], "entity_1_idx_in_text_with_entity_marker": [42, 51], "entity_1_idx_in_text_with_typed_entity_marker": [47, 56], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [267, 273], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_idx_in_text_with_typed_entity_marker": [292, 298], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_279", "text": "The expression of GHRH receptor (GHRHR) is regulated by @GENE$, both of which are known to be expressed in human @DISEASE$ cells.", "text_with_entity_marker": "The expression of GHRH receptor (GHRHR) is regulated by [E1]@GENE$[/E1], both of which are known to be expressed in human [E2]@DISEASE$[/E2] cells.", "text_with_typed_entity_marker": "The expression of GHRH receptor (GHRHR) is regulated by [GENE]@GENE$[/GENE], both of which are known to be expressed in human [DISEASE]@DISEASE$[/DISEASE] cells.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [56, 62], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_idx_in_text_with_typed_entity_marker": [62, 68], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [113, 122], "entity_2_idx_in_text_with_entity_marker": [126, 135], "entity_2_idx_in_text_with_typed_entity_marker": [135, 144], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_22", "text": "The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced @DISEASE$ indicate that patients whose tumors were wild-type, but not mutant, for @GENE$ obtained the most clinical benefit from this combination therapy.", "text_with_entity_marker": "The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced [E1]@DISEASE$[/E1] indicate that patients whose tumors were wild-type, but not mutant, for [E2]@GENE$[/E2] obtained the most clinical benefit from this combination therapy.", "text_with_typed_entity_marker": "The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced [DISEASE]@DISEASE$[/DISEASE] indicate that patients whose tumors were wild-type, but not mutant, for [GENE]@GENE$[/GENE] obtained the most clinical benefit from this combination therapy.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@DISEASE$", "entity_1_idx": [175, 184], "entity_1_idx_in_text_with_entity_marker": [179, 188], "entity_1_idx_in_text_with_typed_entity_marker": [184, 193], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [257, 263], "entity_2_idx_in_text_with_entity_marker": [270, 276], "entity_2_idx_in_text_with_typed_entity_marker": [282, 288], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_71", "text": "The @GENE$ gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (@DISEASE$) in the Japanese population.", "text_with_entity_marker": "The [E1]@GENE$[/E1] gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms ([E2]@DISEASE$[/E2]) in the Japanese population.", "text_with_typed_entity_marker": "The [GENE]@GENE$[/GENE] gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms ([DISEASE]@DISEASE$[/DISEASE]) in the Japanese population.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [4, 10], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_idx_in_text_with_typed_entity_marker": [10, 16], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [96, 105], "entity_2_idx_in_text_with_entity_marker": [109, 118], "entity_2_idx_in_text_with_typed_entity_marker": [118, 127], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_16", "text": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or @GENE$, is involved in the pathogenesis of @DISEASE$.", "text_with_entity_marker": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or [E1]@GENE$[/E1], is involved in the pathogenesis of [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or [GENE]@GENE$[/GENE], is involved in the pathogenesis of [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [76, 82], "entity_1_idx_in_text_with_entity_marker": [80, 86], "entity_1_idx_in_text_with_typed_entity_marker": [82, 88], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [119, 128], "entity_2_idx_in_text_with_entity_marker": [132, 141], "entity_2_idx_in_text_with_typed_entity_marker": [141, 150], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_45", "text": "@GENE$ (Abeta) levels are elevated in the brain of @DISEASE$ patients.", "text_with_entity_marker": "[E1]@GENE$[/E1] (Abeta) levels are elevated in the brain of [E2]@DISEASE$[/E2] patients.", "text_with_typed_entity_marker": "[GENE]@GENE$[/GENE] (Abeta) levels are elevated in the brain of [DISEASE]@DISEASE$[/DISEASE] patients.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [0, 6], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_idx_in_text_with_typed_entity_marker": [6, 12], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [51, 60], "entity_2_idx_in_text_with_entity_marker": [64, 73], "entity_2_idx_in_text_with_typed_entity_marker": [73, 82], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_223", "text": "Elevation of @GENE$ expression in @DISEASE$ with Gsalpha protein mutation.", "text_with_entity_marker": "Elevation of [E1]@GENE$[/E1] expression in [E2]@DISEASE$[/E2] with Gsalpha protein mutation.", "text_with_typed_entity_marker": "Elevation of [GENE]@GENE$[/GENE] expression in [DISEASE]@DISEASE$[/DISEASE] with Gsalpha protein mutation.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [13, 19], "entity_1_idx_in_text_with_entity_marker": [17, 23], "entity_1_idx_in_text_with_typed_entity_marker": [19, 25], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [34, 43], "entity_2_idx_in_text_with_entity_marker": [47, 56], "entity_2_idx_in_text_with_typed_entity_marker": [56, 65], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_141", "text": "@DISEASE$ patients have impaired @GENE$ secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.", "text_with_entity_marker": "[E1]@DISEASE$[/E1] patients have impaired [E2]@GENE$[/E2] secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.", "text_with_typed_entity_marker": "[DISEASE]@DISEASE$[/DISEASE] patients have impaired [GENE]@GENE$[/GENE] secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@DISEASE$", "entity_1_idx": [0, 9], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_idx_in_text_with_typed_entity_marker": [9, 18], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [33, 39], "entity_2_idx_in_text_with_entity_marker": [46, 52], "entity_2_idx_in_text_with_typed_entity_marker": [58, 64], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_134", "text": "Previous studies have demonstrated an association between polymorphisms in the regulatory regions of @GENE$ (CypA) and susceptibility to both HIV-1 @DISEASE$ and disease progression.", "text_with_entity_marker": "Previous studies have demonstrated an association between polymorphisms in the regulatory regions of [E1]@GENE$[/E1] (CypA) and susceptibility to both HIV-1 [E2]@DISEASE$[/E2] and disease progression.", "text_with_typed_entity_marker": "Previous studies have demonstrated an association between polymorphisms in the regulatory regions of [GENE]@GENE$[/GENE] (CypA) and susceptibility to both HIV-1 [DISEASE]@DISEASE$[/DISEASE] and disease progression.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [101, 107], "entity_1_idx_in_text_with_entity_marker": [105, 111], "entity_1_idx_in_text_with_typed_entity_marker": [107, 113], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [148, 157], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_idx_in_text_with_typed_entity_marker": [170, 179], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_47", "text": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in @DISEASE$ cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their @GENE$ expression probably because of their saturation of GHRH signaling.", "text_with_entity_marker": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in [E1]@DISEASE$[/E1] cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their [E2]@GENE$[/E2] expression probably because of their saturation of GHRH signaling.", "text_with_typed_entity_marker": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in [DISEASE]@DISEASE$[/DISEASE] cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their [GENE]@GENE$[/GENE] expression probably because of their saturation of GHRH signaling.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@DISEASE$", "entity_1_idx": [78, 87], "entity_1_idx_in_text_with_entity_marker": [82, 91], "entity_1_idx_in_text_with_typed_entity_marker": [87, 96], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [174, 180], "entity_2_idx_in_text_with_entity_marker": [187, 193], "entity_2_idx_in_text_with_typed_entity_marker": [199, 205], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_17", "text": "@GENE$, IL-1R and TNFalpha gene polymorphisms in Iranian patients with @DISEASE$.", "text_with_entity_marker": "[E1]@GENE$[/E1], IL-1R and TNFalpha gene polymorphisms in Iranian patients with [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "[GENE]@GENE$[/GENE], IL-1R and TNFalpha gene polymorphisms in Iranian patients with [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [0, 6], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_idx_in_text_with_typed_entity_marker": [6, 12], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [71, 80], "entity_2_idx_in_text_with_entity_marker": [84, 93], "entity_2_idx_in_text_with_typed_entity_marker": [93, 102], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_236", "text": "On the other hand, AA genome and A allele polymorphism in the @GENE$ gene nucleotide pair G-A 61 is a significant risk factor for @DISEASE$.", "text_with_entity_marker": "On the other hand, AA genome and A allele polymorphism in the [E1]@GENE$[/E1] gene nucleotide pair G-A 61 is a significant risk factor for [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "On the other hand, AA genome and A allele polymorphism in the [GENE]@GENE$[/GENE] gene nucleotide pair G-A 61 is a significant risk factor for [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [62, 68], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_idx_in_text_with_typed_entity_marker": [68, 74], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [130, 139], "entity_2_idx_in_text_with_entity_marker": [143, 152], "entity_2_idx_in_text_with_typed_entity_marker": [152, 161], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_1", "text": "Two hundred and twenty-three incident @DISEASE$ cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, @GENE$, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "text_with_entity_marker": "Two hundred and twenty-three incident [E1]@DISEASE$[/E1] cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, [E2]@GENE$[/E2], Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "text_with_typed_entity_marker": "Two hundred and twenty-three incident [DISEASE]@DISEASE$[/DISEASE] cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, [GENE]@GENE$[/GENE], Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@DISEASE$", "entity_1_idx": [38, 47], "entity_1_idx_in_text_with_entity_marker": [42, 51], "entity_1_idx_in_text_with_typed_entity_marker": [47, 56], "entity_1_type": "DISEASE", "entity_1_type_id": 1, "entity_2": "@GENE$", "entity_2_idx": [540, 546], "entity_2_idx_in_text_with_entity_marker": [553, 559], "entity_2_idx_in_text_with_typed_entity_marker": [565, 571], "entity_2_type": "GENE", "entity_2_type_id": 0}]}
{"id": "train_5_205", "text": "The 5T5T genotype at @GENE$ SNP -1613 5T/6T increased the chance of stenotic complications in @DISEASE$ during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).", "text_with_entity_marker": "The 5T5T genotype at [E1]@GENE$[/E1] SNP -1613 5T/6T increased the chance of stenotic complications in [E2]@DISEASE$[/E2] during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).", "text_with_typed_entity_marker": "The 5T5T genotype at [GENE]@GENE$[/GENE] SNP -1613 5T/6T increased the chance of stenotic complications in [DISEASE]@DISEASE$[/DISEASE] during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@GENE$", "entity_1_idx": [21, 27], "entity_1_idx_in_text_with_entity_marker": [25, 31], "entity_1_idx_in_text_with_typed_entity_marker": [27, 33], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [94, 103], "entity_2_idx_in_text_with_entity_marker": [107, 116], "entity_2_idx_in_text_with_typed_entity_marker": [116, 125], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_15", "text": "@GENE$ protein is an extracellular matrix molecule initially cloned from human @DISEASE$ cells treated with TGF-beta.", "text_with_entity_marker": "[E1]@GENE$[/E1] protein is an extracellular matrix molecule initially cloned from human [E2]@DISEASE$[/E2] cells treated with TGF-beta.", "text_with_typed_entity_marker": "[GENE]@GENE$[/GENE] protein is an extracellular matrix molecule initially cloned from human [DISEASE]@DISEASE$[/DISEASE] cells treated with TGF-beta.", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [0, 6], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_idx_in_text_with_typed_entity_marker": [6, 12], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [79, 88], "entity_2_idx_in_text_with_entity_marker": [92, 101], "entity_2_idx_in_text_with_typed_entity_marker": [101, 110], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_107", "text": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and @GENE$) were strikingly over-represented among forty-five Long Term @DISEASE$ controllers.", "text_with_entity_marker": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and [E1]@GENE$[/E1]) were strikingly over-represented among forty-five Long Term [E2]@DISEASE$[/E2] controllers.", "text_with_typed_entity_marker": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and [GENE]@GENE$[/GENE]) were strikingly over-represented among forty-five Long Term [DISEASE]@DISEASE$[/DISEASE] controllers.", "relation": [{"relation_type": "negative", "relation_id": 0, "entity_1": "@GENE$", "entity_1_idx": [118, 124], "entity_1_idx_in_text_with_entity_marker": [122, 128], "entity_1_idx_in_text_with_typed_entity_marker": [124, 130], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [186, 195], "entity_2_idx_in_text_with_entity_marker": [199, 208], "entity_2_idx_in_text_with_typed_entity_marker": [208, 217], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
{"id": "train_5_316", "text": "In the case-control association analysis, the @GENE$ polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with @DISEASE$.", "text_with_entity_marker": "In the case-control association analysis, the [E1]@GENE$[/E1] polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with [E2]@DISEASE$[/E2].", "text_with_typed_entity_marker": "In the case-control association analysis, the [GENE]@GENE$[/GENE] polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with [DISEASE]@DISEASE$[/DISEASE].", "relation": [{"relation_type": "positive", "relation_id": 1, "entity_1": "@GENE$", "entity_1_idx": [46, 52], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_idx_in_text_with_typed_entity_marker": [52, 58], "entity_1_type": "GENE", "entity_1_type_id": 0, "entity_2": "@DISEASE$", "entity_2_idx": [230, 239], "entity_2_idx_in_text_with_entity_marker": [243, 252], "entity_2_idx_in_text_with_typed_entity_marker": [252, 261], "entity_2_type": "DISEASE", "entity_2_type_id": 1}]}
